A Cohort Study to Determine the Incidence of Dengue Fever and to Build Capacity for Dengue Vaccine Trials in Dengue-endemic Regions of South Asia

NACompletedINTERVENTIONAL
Enrollment

2,004

Participants

Timeline

Start Date

June 1, 2016

Primary Completion Date

June 28, 2019

Study Completion Date

June 28, 2019

Conditions
Dengue
Interventions
PROCEDURE

Blood sample collection

Blood samples will be collected during the Suspected Dengue First Visit. All study subjects with AFI (fever \[body temperature ≥ 38°C/≥ 100.4°F\] on ≥ 2 consecutive calendar days, measured at least twice, at least 8 hours apart) should be seen at a designated study hospital/clinic by the study physician. The Suspected Dengue First Visit should be scheduled within 7 days from the onset of fever (Days 2-7) and should ideally take place on the second day of fever (Day 2).

Trial Locations (1)

Unknown

GSK Investigational Site, Colombo

Sponsors

Lead Sponsor

All Listed Sponsors
collaborator

Ministry of Health, Sri Lanka

OTHER_GOV

lead

GlaxoSmithKline

INDUSTRY

NCT02570152 - A Cohort Study to Determine the Incidence of Dengue Fever and to Build Capacity for Dengue Vaccine Trials in Dengue-endemic Regions of South Asia | Biotech Hunter | Biotech Hunter